NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
28 trialsNCT01679119 2026-04-07
INCA
University College, London
Phase 2 Completed
NCT06890884 2026-04-02
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT04479267 2025-09-29
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Active not recruiting
NCT07035379 2025-08-22
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1/2 Not yet recruiting
NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT06594640 2025-05-14
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT04914741 2024-08-12
COALITION
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT05990985 2023-08-18
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
The First Hospital of Jilin University
Phase NA Not yet recruiting
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT03899337 2023-01-09
STELLAR
University of Birmingham
Phase 2 Recruiting
NCT03465527 2022-04-01
Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL
Kosin University Gospel Hospital
Phase 2 Completed
NCT05280626 2022-03-15
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting
NCT02890602 2020-02-20
Erythropoietin for Management of Anemia Caused by Chemotherapy
Kosin University Gospel Hospital
Phase 2 Completed
NCT01724021 2018-01-23
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
Phase 3 Completed
NCT01324596 2016-04-15
REMoDL-B
University Hospital Southampton NHS Foundation Trust
Phase 3 Completed
NCT00971763 2014-12-04
Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University College, London
Phase 2 Completed
NCT00003815 2013-09-17
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00575406 2013-08-30
NHL-14
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00002576 2013-08-07
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005867 2013-06-26
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00379574 2013-03-15
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Asan Medical Center
Phase 1/2 Completed
NCT00689845 2009-07-08
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase NA Unknown